CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Mid-cap biotechs join Trump’s latest round of drug pricing deals

Neutral
AI Analysis

Summary

Mid-cap biotechs, including IBO, have joined Trump's new drug pricing agreements focused on Medicaid. The deals, while expanding beyond large pharmaceutical companies, are not expected to materially impact drugmaker profitability.

Importance:3/10
Sentiment:
0.00
drug pricingMedicaidTrump administrationpolicy
Related Companies

Read the original article

Published by BioPharma Dive on September 1, 2026 4:14 PM

Read Original